Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition

Abstract Purpose The human double minute 2 homolog hdm2, alias mdm2, is the main negative-regulator of the tumor suppressor p53. In that capacity, mdm2 is a promising but not yet utilized molecular target for the treatment of breast cancer, however, its inhibition by small molecules is rather inappr...

Full description

Saved in:
Bibliographic Details
Main Authors: Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff
Format: Article
Language:English
Published: BMC 2025-06-01
Series:BMC Cancer
Subjects:
Luminal breast cancer
Estrogen receptor-positive breast cancer
mdm2
p53 mutation
Abemaciclib
PROTAC
Online Access:https://doi.org/10.1186/s12885-025-14361-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items